s 2020 0057

The invention relates to medicine, in particular to pediatric neurology, neonatology, pediatrics, and can be used for predicting the course of neuropsychomotor disorders in children with ischemic cerebral stroke.

Summary of the invention consists in that the patient of pediatric age undergoes the clinical and paraclinical examination, the clinical picture of brain structure affection is established, at the same time 2...3 ml of venous blood is sampled, centrifuged, the blood serum is separated and stored at a constant temperature of -20°C, the serum concentration of vascular endothelial growth factor, S100B protein and endoglin is determined, if the serum concentration of vascular endothelial growth factor is 1705.81...716.80 pg/ml, of S100B protein is 1.024...0.720 pg/ml and of endoglin is 1.90...2.11 pg/ml, a severe course ma neuropsychomotor disorders is predicted; if the serum concentration of vascular endothelial growth factor is 716.80...450.41 pg/ml, of S100B protein is 0.720...0.399 pg/ml and of endoglin is 2.11...2.24 pg/ml, a course of moderate severity of neuropsychomotor disorders is predicted; if the serum concentration of vascular endothelial growth factor is 450.41...296.23 pg/ml, of S100B protein is 0.399...0.272 pg/ml and of endoglin is 2.24...2.29 pg/ml, a course of mild severity of neuropsychomotor disorders is predicted.

Claims: 1

*